STOCK TITAN

Aspira Women's Health to restate Q1, H1 2026 cash flows

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. said its unaudited cash-flow statements for the three months ended March 31, 2026, and six months ended June 30, 2026, should no longer be relied upon and plans to restate them. A January 2026 loan and related payments had been classified in operating rather than financing activities. As restated, net cash used in operating activities was $1.119 million for the three-month period and $2.677 million for the six-month period; net cash provided by financing activities was $708,000 and $1.549 million, respectively.

The reclassification did not affect previously reported balance sheets, statements of operations, or the total net change in cash, cash equivalents and restricted cash. Management identified a material weakness in internal control over financial reporting and concluded that internal controls and disclosure controls were ineffective for the affected periods. The company is enhancing procedures for significant, non-routine or complex transactions; the weakness will not be considered remediated until controls operate for sufficient time and management testing finds them effective.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major pointAWHL reported a material weakness; controls were ineffective as of March 31 and June 30, 2026.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.AWHL’s March and June 2026 cash-flow statements require restatement.
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review Governance
Previously issued financial statements, a related audit report, or a completed interim review should no longer be relied upon.
Net cash used in operating activities $1.119 million Three months ended March 31, 2026, as restated; previously reported $359,000 used.
Net cash provided by financing activities $708,000 Three months ended March 31, 2026, as restated; previously reported net cash used of $52,000.
Net cash used in operating activities $2.677 million Six months ended June 30, 2026, as restated; previously reported $2.369 million used.
Net cash provided by financing activities $1.549 million Six months ended June 30, 2026, as restated; previously reported $1.241 million provided.
Proceeds from January 2026 Agile Loan $1.05 million Reported in financing activities for the three- and six-month periods ended March 31 and June 30, 2026, respectively.
ASC Topic 230, Statement of Cash Flows technical
"under Accounting Standards Codification (“ASC”) Topic 230, Statement of Cash Flows"
material weakness regulatory
"resulted in a material weakness in the Company’s internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
internal control over financial reporting regulatory
"material weakness in the Company’s internal control over financial reporting"
Internal control over financial reporting is a company’s system of procedures and checks designed to make sure its financial statements are accurate and complete, like a set of guardrails and verification steps that catch mistakes or fraud before numbers are published. Investors care because strong controls make reported results more trustworthy, lower the risk of surprise restatements or regulatory problems, and give greater confidence when valuing the company or comparing it to peers.
disclosure controls and procedures regulatory
"its disclosure controls and procedures were ineffective"
Policies, routines and internal checks a public company uses to identify, collect and verify information that must appear in its financial reports and public filings, and to make sure that material news is disclosed accurately and on time. Investors care because effective controls increase confidence that the company’s reported numbers and disclosures are reliable and reduce the risk of surprises, much like a building’s inspection and alarm system helps occupants trust the structure’s safety.
debt issuance costs financial
"Amortization of debt issuance costs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is AWHL restating its 2026 cash-flow statements?

Aspira Women’s Health identified a classification error in the January 2026 Agile Loan proceeds and related payments: they had been reported in operating activities rather than financing activities under ASC Topic 230. The restatement changes cash-flow presentation, not the total net change in cash, cash equivalents and restricted cash.

Which AWHL financial periods are affected by the restatement?

The affected periods are the three months ended March 31, 2026, and the six months ended June 30, 2026. Aspira said the unaudited statements in its quarterly reports for those periods should no longer be relied upon and plans to restate them.

Did AWHL’s restatement change its total cash movement?

No. Aspira said the restatement had no impact on the previously reported total net change in cash, cash equivalents and restricted cash, or on its balance sheets and statements of operations.

What internal control issue did AWHL report?

Aspira identified a material weakness in internal control over financial reporting and concluded that its internal control over financial reporting and disclosure controls and procedures were ineffective for the affected periods. The weakness will not be considered remediated until the applicable controls operate for sufficient time and management testing shows they are effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Aspira Women's Health Inc.0000926617false00009266172026-01-302026-01-30

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  November 16, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

  ​ ​ ​

001-34810

  ​ ​ ​

33-0595156

(State or other jurisdiction of

​

(Commission

​

(IRS Employer

incorporation or organization)

​

File Number)

​

Identification No.)

​

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, par value $0.001

​

AWHL

​

OTC QX Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

​

On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Aspira Women’s Health Inc. (the “Company”), after discussion with management and the Company’s independent registered public accounting firm, concluded that the Company’s previously issued unaudited Condensed Consolidated Financial Statements as of and for the three and six months ended March 31, and June 30, 2026 (the “Affected Periods”) included in the Company’s Quarterly Reports on Form 10-Q filed on May 15, 2026, and August 14, 2026, should no longer be relied upon due to material errors in the unaudited Condensed Consolidated Statement of Cash Flows.

​

During the preparation of its financial statements for the period ended September 30, 2026, management identified errors in the presentation and classification of certain loan proceeds and related payments under Accounting Standards Codification (“ASC”) Topic 230, Statement of Cash Flows. Specifically, the restatement reflects the correction of the recording of a loan obtained in January 2026 and related payments that were previously reported within operating activities in the Statement of Cash Flows rather than financing activities.  

 

These restatement adjustments had no impact on the Company’s previously reported unaudited Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations or total net change in cash, cash equivalents, and restricted cash for the Affected Periods.  

 

The following table presents the impact of the restatement on the Company’s unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2026 (in thousands): 

 

​

​

​

​

Statement of Cash Flows – Three Months ended March 31, 2026 

As Previously Reported  

Restatement Adjustments 

As Restated 

Cash Flows from Operating Activities   

​

​

​

Amortization of debt issuance costs  

 $              -    

 $             15  

 $             15  

Other liabilities   

 $       1,380  

 $          (775) 

 $            605  

Net cash used in operating activities 

 $        (359) 

 $          (760) 

 $      (1,119) 

​

​

​

​

Cash Flows from Financing Activities   

​

​

​

Proceeds from Jan. 2026 Agile Loan  

 $              -    

 $         1,050  

 $         1,050  

Principal repayments of Jan. 2026 Agile loan  

 $              -    

 $          (240) 

 $         (240) 

Payment of debt issuance costs  

 $              -    

 $            (50) 

 $           (50) 

Net cash provided by financing activities 

 $         (52) 

 $           760 

 $            708 

​

​

The following table presents the impact of the restatement on the Company’s unaudited Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2026 (in thousands): 

​

​

​

​

​

Statement of Cash Flows – Six Months ended June 30, 2026 

As Previously Reported  

Restatement Adjustments 

As Restated 

Cash Flows from Operating Activities  

  ​

  ​

  ​

Amortization of debt issuance costs  

 $              -    

 $             37  

 $             37  

Other liabilities   

 $            53  

 $          (345) 

 $         (292) 

Net cash used in operating activities 

 $     (2,369) 

 $          (308) 

 $      (2,677) 

​

​

​

​

Cash Flows from Financing Activities   

  ​

  ​

  ​

Proceeds from Jan. 2026 Agile Loan  

 $              -    

 $         1,050  

 $         1,050  

Principal repayments of Jan. 2026 Agile loan  

 $              -    

 $          (692) 

 $         (692) 

Payment of debt issuance costs  

 $              -    

 $            (50) 

 $           (50) 

Net cash provided by financing activities 

 $       1,241 

 $           308 

 $         1,549 

​

​

The Company plans to restate the unaudited Condensed Consolidated Financial Statements contained in the Company’s Quarterly Reports on Form 10-Q for the three months ended March 31, 2026 and the six months ended June 30, 2026. 

​

The Company’s management evaluated its prior conclusions regarding the effectiveness of the Company’s disclosure controls and procedures and internal control over financial reporting. Based on that evaluation, management has concluded that this matter resulted in a material weakness in the Company’s internal control over financial reporting, which will be disclosed in Item 9A of the Form 10-Q/A. As a result of the material weakness, the Company has concluded that its internal control over financial reporting and its disclosure controls and procedures were ineffective as of the periods referenced above. The Company is taking steps to enhance its procedures and controls surrounding the accounting for significant, non-routine or complex transactions and will continue to refine these procedures and controls. The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient time and management has concluded, through testing, that these controls are operating effectively.

​

The Audit Committee has discussed with BDO USA, P.C., the Company’s independent registered public accounting firm, matters disclosed in this Item 4.02 Form 8-K.

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 16, 2026

​

 

ASPIRA WOMEN’S HEALTH INC.

 

 

 

 

By:

/s/ John Strahley

 

Name: 

John Strahley

 

Title:

Chief Financial Officer

​

Filing Exhibits & Attachments

3 documents

Keep reading